Enlicitide
Highest phase reached
Phase 3
Drug type
Protein
- Listing at source
- Listed
- Highest phase reached
- Phase 3
- Drug type
- Protein
- Drug name
- Enlicitide
- Molecular weight
- 1,550.86
- Structure (SMILES)
- COc1ccc(C[C@@H]2NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H]3[C@@H]4CCN3C(=O)[C@@H]3Cc5cn(c6ccc(F)cc56)CCCCCCN(Cc5ccc(cc5)CCNC(=O)[C@]5(C)CCCN5C2=O)C(=O)CCC(=O)N[C@@H](C)C(=O)N[C@H](CNC(=O)CCCCC[N+](C)(C)C)C(=O)N[C@@H](Cc2cccc(c2)CNC(=O)CO4)C(=O)N3)cc1
- CAS registry numbers
- 2407527-14-2
- ChEMBL ID
- CHEMBL6068773
- InChIKey
- ZJMSWDDEBKNMLX-HMPNVHCESA-O
- PubChem compound IDs
- 164933665
- RxNorm IDs (RxCUI)
- 2747751
- FDA ingredient codes (UNII)
- R7EZ772VG2
- First in class
- No
- Orphan designation
- No
- Pharmacology name
- enlicitide
- Type
- Peptide
- Drug name stem
- -tide
- Approval recorded by Guide to Pharmacology
- Yes
Mechanisms of action
- Action
- Binding
- Action type
- Binding
- Target
- proprotein convertase subtilisin/kexin type 9
- Gene symbol
- PCSK9
- Protein identifier
- Q8NBP7
- Median affinity
- 11.3
- Affinity units
- pKi
- Condition identifier
- HP_0003124
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0005439
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0021187
- Highest recorded phase
- 3
- Calculated partition coefficient (XLogP)
- 4.2
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Heavy atoms
- 112
- Molecular formula
- C82H110FN14O15+
- Monoisotopic mass
- 1549.82591202
- Natural product
- No
Related records
Trials (14)
- A Clinical Study of Enlicitide and the Effect of Food in Healthy Adult Participants (MK-0616-033)
- A Clinical Study of Enlicitide Decanoate in People With Liver Function Problems (MK-0616-030)
- A Clinical Study of Enlicitide in Participants With High Cholesterol (MK-0616-037)
- A Clinical Study of Enlicitide in Participants With Severe Renal Impairment (MK-0616-032)
- A Clinical Study of How Coffee and Tea Affect Enlicitide in Healthy Volunteers (MK-0616-040)
- A Clinical Study of MK-7262 and Enlicitide in Healthy Participants (MK-7262-003)
- A Clinical Study of the Effect of Enlicitide (MK-0616) Formulations in Healthy Participants (MK-0616-041)
- A Clinical Study to Assess the Effect of Enlicitide on How the Body Processes Digoxin in Healthy Adult Participants (MK-0616-031)
- A Clinical Study to Evaluate Enlicitide (MK-0616) Formulations in Healthy Adult Participants (MK-0616-035)
- A Clinical Trial of Enlicitide (MK-0616) Formulations in Healthy Participants (MK-0616-044)
- A Clinical Trial of Enlicitide and Rosuvastatin in Healthy Adults (MK-0616-039)
- A Clinical Trial of MK-7262 and Enlicitide in Participants With High Lipoprotein(a) (MK-7262-004)
- A Study of Lithium and Enlicitide in Healthy Adult Participants (MK-0616-034)
- A Study to Evaluate the Efficacy and Safety of Enlicitide (MK-0616, Oral PCSK9 Inhibitor) Compared With Ezetimibe or Bempedoic Acid or Ezetimibe and Bempedoic Acid in Adults With Hypercholesterolemia (MK-0616-018/CORALreef AddOn)
In development for (2)
- Familial hypercholesterolemia Phase 3
- Hyperlipidemia Phase 3